What Has Been The Historical And Current Growth Of The Follicular Lymphoma Treatment Market?
The follicular lymphoma treatment market has seen considerable growth due to a variety of factors.
•The market for follicular lymphoma treatment has experienced robust expansion in the past few years. It is projected to surge from $3.05 billion in 2024 to $3.31 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.5%.
This significant growth during the historical period can be traced back to the rising incidence of follicular lymphoma, advances in cancer diagnostic techniques, an increasing elderly population, advancements in clinical research and drug development, and oncology research collaborations.
What Is The Forecast For The Follicular Lymphoma Treatment Market By 2029?
The follicular lymphoma treatment market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for follicular lymphoma treatment is projected to witness substantial growth. It is anticipated to reach "$4.57 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%.
This market growth during the predicted period is credited to the adoption of personalized medicine methodologies, advancements in immunotherapy, wider availability of innovative treatments, emphasis on life quality, and international initiatives for oncology collaboration. Key trends for the forecast period comprise clinical studies and research efforts, the investigation of epigenetic modulators, progress in radioimmunotherapy, the utilization of artificial intelligence (AI), and worldwide collaboration for therapies accessibility.
Which Key Drivers Are Propelling The Follicular Lymphoma Treatment Market's Growth?
The increasing incidence of follicular lymphoma is anticipated to stimulate the advancement of the follicular lymphoma treatment market. Follicular lymphoma prevalence is the sum or rate of individuals in a particular population that have been diagnosed with follicular lymphoma at any given time or over a specific time-frame. Factors contributing to this development include an aging population, genetic factors, enhanced diagnostic methodologies, and heightened consciousness and screening. Treatments for follicular lymphoma can mitigate its prevalence by addressing the illness in various phases, aiding in its management and progression. The growing occurrence of follicular lymphoma is supporting the expansion of the follicular lymphoma treatment market. As an example, in January 2023, data from The American Cancer Society, a US-based volunteer organization, revealed that non-Hodgkin lymphoma, a form of lazy follicular lymphoma, is the most common cancer in the US, representing about 4% of all cancers. The American Cancer Society predicts that around 80,550 individuals will be diagnosed with NHL (of which 44,880 will be men and 35,670 will be women) - this figure includes both adults and children. As such, the increasing frequency of follicular lymphoma is contributing to the growth of the follicular lymphoma treatment market.
What Are The Key Segments Within The Global Follicular Lymphoma Treatment Market?
The follicular lymphoma treatment market covered in this report is segmented –
1) By Treatment: Monoclonal Antibodies, Targeted Therapy, Chemotherapy, Radiation Therapy, Stem Cell Transplant, Alkylating Agents, Nucleoside Analogues, Anthracycline Derivatives, Other Treatments
2) By Product Type: Tablets, Capsules, Injectables, Other Product Types
3) By Route of Administration: Oral, Parenteral, Other Route of Administration
4) By End Use: Hospitals, Oncology Centers, Ambulatory Care Centers, Academic Research Institutes, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Rituximab, Obinutuzumab, Ofatumumab
2) By Targeted Therapy: PI3K Inhibitors, BTK Inhibitors, BCL-2 Inhibitors
3) By Chemotherapy: CHOP Regimen, Bendamustine, Fludarabine
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioimmunotherapy
5) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
6) By Alkylating Agents: Cyclophosphamide, Ifosfamide
Pre-Book The Follicular Lymphoma Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Follicular Lymphoma Treatment Market?
The expanding application of technology in diagnosing and treating follicular lymphoma is an emerging trend providing potential growth in the follicular lymphoma treatment market. Companies engaged in this market are leveraging advanced diagnosis and treatment methods to maintain their market dominance. For instance, in December 2022, Genentech Inc., a biotech firm based in the US, gained FDA approval for Lunsumio, an innovative bispecific antibody designed to treat relapsed or refractory follicular lymphoma. This antibody represents a fresh approach to fixed-duration cancer treatment immunotherapy. It's a readily accessible and off-the-shelf treatment option, obviating the need for patients to wait for this immunotherapy treatment. The FDA's approval was driven by positive outcomes from the Lunsumio Phase II GO29781 study on individuals with extensively pretreated FL, especially those at high risk of disease progression or lack of response to preceding treatments.
Who Are the Key Players in the Follicular Lymphoma Treatment Market?
Major companies operating in the follicular lymphoma treatment market include:
• AbbVie Inc.
• Bayer AG
• Bristol Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Johnson and Johnson Services Inc.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co. Inc.
• EpiZyme Inc.
• Boehringer Ingelheim GmbH
• CTI BioPharma Corp.
• Spectrum Pharmaceuticals Inc.
• Seattle Genetics Inc.
• Applied Molecular Genetics Inc.
• Daiichi Sankyo Company Ltd.
• Pfizer Inc.
• Incyte Corporation
• MorphoSys AG
• Regeneron Pharmaceuticals Inc.
• Eli Lilly and Company
• Seagen Inc.
• Takeda Pharmaceutical Company
• Nordic Nanovector ASA
• ADC Therapeutics SA
• MEI Pharma Inc.
• BeiGene Inc.
• TG Therapeutics Inc.
• Amgen Inc.
• Dr. Reddy's Laboratories Ltd.
What are the Regional Insights into the Follicular Lymphoma Treatment Market?
North America was the largest region in the follicular lymphoma treatment market in 2024. The regions covered in the follicular lymphoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
